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L-2 hydroxyglutaric aciduria is an autosomal recessive error of metabolism that manifests as 
an encephalopathy. The most common presenting signs are seizures, tremors, ataxia and/
or dementia. Some affected dogs show only subtle behavioural changes. Amongst canines, 
the condition has been best described in Staffordshire Bull Terriers. Although this is the 
first reported case in South Africa, at least three other affected dogs have been indentified 
by polmerase chain reaction (PCR) in this country. Affected dogs have normal haematology, 
serum biochemistry and routine urine analysis. This report discusses the advantages and 
limitations of the three main diagnostic modalities, namely: magnetic resonance imaging, 
urine gas chromatography-mass spectrometry and genetic testing. The aim of this report is 
to increase awareness of the condition, assist diagnosis in encephalopathic dogs and improve 
detection of carriers amongst breeding stock.
Introduction 
L-2 hydroxyglutaric aciduria (L2-HGAU) was first reported in humans in 1980 (Duran et al. 
1980). To date, case reports on well over 100 patients have been published (Kranendijk et al. 
2012; Steenweg et al. 2010). In 2003, Abramson and others described six-affected Staffordshire 
Bull Terriers (SBT) in the United Kingdom (Abramson et al. 2003). Since then, L2-HGAU has also 
been documented in three Yorkshire Terriers (YRT) (Farias et al. 2012; Sanchez-Masian et al. 2012) 
and one West Highland White Terrier (Garosi et al. 2005). The causative mutations in YRT differ 
from those in SBT (Farias et al. 2012; Penderis et al. 2007; Sanchez-Masian et al. 2012). Whilst all 
tested SBT have had the same mutation in the L2 hydroxyglutarate dehydrogenase gene (L2-
HGDH) (Penderis et al. 2007), over 80 different mutations of L2-HGDH have been demonstrated 
in affected humans (Kranendijk et al. 2012; Steenweg et al. 2010). 
Case history
A  5-year-old,  18.3  kg,  female,  neutered  SBT  was  referred  to  the  first  author  for  further 
investigation of an episode of bizarre behaviour or dementia. 
In retrospect, her owners had observed mild ataxia for 11 months prior to presentation; she 
appeared somewhat unsteady for a few seconds when she woke up, occasionally banged into 
walls on cornering and at times had difficulty climbing steps. Signs would wax and wane and 
were too subtle to prompt consultation with a veterinarian.
The first episode of bizarre behaviour occurred nine months prior to presentation, lasted for a day 
and resolved without treatment. The dog appeared disorientated and aggressive, was pacing and 
restless, panting and hyperactive. She did not respond to commands where she was normally 
biddable. 
The episode that prompted the investigation lasted for a week. Initially, she became unusually 
aggressive toward the neighbour’s dog and attacked the garbage bins. Signs gradually worsened 
and two days later she had stopped responding to commands, spent all night pacing and appeared 
disorientated with impaired spatial perception and balance. She urinated indoors and showed no 
awareness of the fact that this had happened. On the third symptomatic day she was presented 
to her usual veterinarian. She was treated with alprazolam (1.75 mg bid) (Adco-Alzem, Adcock 
Ingram Pharmaceuticals, Bryanston, South Africa), which caused transient sedation, after which 
the above behaviour resumed. The next day procaine benzylpenicillin with dihydrostreptomycin 
(dose not recorded) (Depomycin, Intervet-Schering Plough, Isando, South Africa), alprazolam, 
dexamethazone (dose not recorded) (Dexa 0.2 Phenix, Virbac, Halfway House, South Africa) 
and phenobarbitone (30 mg bid) (Lethyl, Aspen Pharmacare, Gallo Manor, South Africa) were 
administered. Her owners reported that she had appeared calmer and had slept for the first time 
in two days following these treatments. She was referred to a specialist the following day, which 
was Day 5 of this episode.
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On clinical examination the dog appeared disorientated. She 
was staring into space, becoming fixated on and staring at 
objects (e.g. a lead), pacing, circling, and walking into a wall. 
A complete clinical and neurological examination revealed 
no further abnormalities.
Results  of  haematology,  serum  biochemistry,  electrolytes, 
random cortisol, basal ammonia and a bile acid stimulation 
test were all within normal reference ranges. Urine analysis 
revealed only hyposthenuria (SG 1.005).
Anaesthesia  was  induced  with  intravenous  propofol  at 
3.33  mg/kg  (Propofol  1.0%  Fresenius,  Fresenius  Kabi, 
Halfway House, South Africa) and was maintained with a 
constant rate infusion of propofol 0.20 mg/kg/min in saline 
(5  mL/kg/min)  (Sabax  Sodium  Chloride  0.9%,  Adcock 
Ingram,  Johannesburg,  South  Africa).  The  following  MRI 
sequences were acquired using an eight-channel head array 
coil in a GE 1.5T Sigma Excite HD MRI scanner: transverse 
T2, transverse T2 FLAIR, sagittal T1, sagittal T2 and coronal 
T2 FLAIR and axial T1. Further sagittal and transverse T1 
sequences  were  acquired  after  intravenous  administration 
of 1.8 mmol gadolinium (Dotarem, Gd-DOTA 27.93% m/v, 
0.5  mmol/mL,  Guerbet,  Villepinte,  France).  The  MRI  was 
interpreted by one of the co-authors (SB). A subtle bilateral 
symmetrical  T2  hyperintensity  was  evident,  involving  the 
regions of the basal ganglia, central and posterior tectum. 
No  contrast  enhancement  was  evident  and  no  other 
abnormalities were reported. MRI changes were consistent 
with a metabolic or toxic encephalopathy. 
A  single  free  flow  urine  sample  was  collected  from  the 
patient and submitted to the UCT/NHLS laboratory (Red 
Cross  Children’s  Hospital,  Cape  Town)  for  organic  acid 
analysis  by  gas  chromatography–mass  spectrometry  (GC-
MS)  as  previously  described  (Van  der  Watt  et  al.  2010). 
Urine  from  a  clinically  normal  five-year-old  female  entire 
Doberman  bitch  was  used  as  a  control.  The  organic  acid 
spectrum from the patient revealed significant lactic aciduria 
and a large 2-hydroxyglutaric acid component (quantified 
at  360  mmol/mol  creatinine).  2-Hydroxyglutaric  acid  was 
not  detected  in  the  control  canine  urine  (Figure  1).  The 
patient’s urine organic acid profile was highly suggestive of 
L2-HGAU, as previously reported in SBTs (Abramson et al. 
2003). 
EDTA  blood  was  submitted  to  Inqaba  Biotec  (Hatfield, 
Pretoria, South Africa) to determine whether the causative 
mutation  was  present.  DNA  was  extracted  and  followed 
with  a  polymerase  chain  reaction  (PCR)  to  amplify  the 
gene of interest. The causative mutation is known to be in 
exon 10 of chromosome 8 in SBT and consists of two single-
nucleotide substitutions separated by a single T nucleotide 
(c[1297TRC; 1299cRt]). This results in the substitution of two 
adjacent  amino  acids:  proline  replaces  leucine  at  position 
433 and tyrosine replaces histidine at position 434 (Penderis 
et al. 2007). An ABI PRISM™ 3130 Genetic Analyzer was used 
to determine the nucleotide sequences in the amplicons. The 
dog was shown to be homozygous for the dicodon mutation 
in L2-HGDH (Figure 2).
The patient was maintained on low doses of phenobarbitone 
(30 mg in the  morning  and 45 mg in  the  evening;  serum 
phenobarbitone 49.8 μmol/L – therapeutic range 43 μmol/L 
–172  μmol/L)  until  she  was  relocated  with  her  owners. 
On the three occasions when the first author observed the 
patient in the three months after her initial diagnosis she still 
appeared mildly dazed. The dose was reduced to 15 mg in 
the morning and 30 mg in the evening at some stage, at the 
recommendation of another veterinarian. Supplementation 
with  100  mg  riboflavin  daily  started  immediately  after 
diagnosis. Her owners considered her back to normal and 
no further severe episodes were observed for the remainder 
of her life. She was treated with both medications until she 
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X-axis, gas chromatography column compound elution times; Y-axis, Fragment ion abundancee 
in arbitrary units
Note: The scales on the Y-axis differ.
FIGURE 1: Aligned GC-MS spectra of urine organic acids from (a) a control dog 
and (b) the Staffordshire Bull Terrier investigated for 2-hydroxyglutaric aciduria. 
Note: This chromatogram shows the nucleotide sequence of the L2-HGDH gene, the gene 
which when mutated results in clinical signs of L2-HGAU. The consensus sequence (top 
row) is the nucleotide sequence of the sample. The trace data show the actual nucleotides 
that were detected in this sample. Below the trace data line, three reference samples were 
sequenced, namely: a dog that was diagnosed as affected by L2-HGA, a heterozygote and 
a clear or normal dog. The two vertical red lines indicate the mutations. A carrier has two 
nucleotides at both mutation positions indicated with a ‘Y’ at both positions. This figure 
shows that the gene sequence of the sample tested corresponded to the sequence of the 
reference sample from an affected dog.
FIGURE 2: Chromatogram of the nucleotide sequences.
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ruptured bilateral cruciate ligaments, prompting euthanasia 
16 months after diagnosis. 
 
Discussion
This is the first report of L2-HGAU in SBT in South Africa. 
Samples  from  200  South  African  SBT  were  submitted  to 
Inqaba  Biotec,  a  commercial  laboratory,  for  determination 
of the dogs’ L2-HGDH status between 2009 and 2012. The 
laboratory  detected 46 heterozygotes  (23%) and four (2%) 
affected dogs (H. van der Zwan [Inqaba Biotec] pers. comm., 
04 Dec. 2012). This confirms that the mutation is present in 
the South African SBT population and dogs showing clinical 
signs of L2-HGAU are likely to be presented periodically to 
veterinarians. 
A  study  of  130  normal  UK  SBT  and  131  normal  Finnish 
SBT  selected  from  two  DNA  archives  detected  L2-HGDH 
heterozygotes in 11% of both populations (Short et al. 2010). 
The same authors searched for the SBT L2-HGDH mutations in 
residual blood samples submitted for routine phenobarbitone 
monitoring from over 1000 epileptic dogs of other breeds and 
found no carrier dogs (Short et al. 2010). Thus, the mutations 
described by Penderis et al. (2007) are either specific to the 
SBT  breed  or  occur  at  a  very  low  frequency  in  epileptic 
dogs of other breeds. The higher proportion of carriers and 
affected dogs recorded by Inqaba Biotec is expected because 
their data merely reflect the incidence of positive samples 
submitted to a commercial laboratory and do not represent 
a random sampling of the South African SBT population. 
Staffordshire Bull Terrier breeders who had become aware 
of  L2-HGAU  and  were  screening  their  breeding  stock 
submitted most samples. It is not known what proportion 
of  the  sampled  SBTs  was  symptomatic  or  had  known, 
affected relatives. Carrier and affected dogs identified by the 
laboratory originated from different breeding lines and lived 
in kennels dispersed throughout South Africa.
L2-HGAU  has  been  called  a  deficiency  of  ‘metabolic 
repair’.  L2-HGA  is  produced  because  the  mitochondrial 
enzyme  L-malate  dehydrogenase  is  not  specific  for  its 
primary substrate, oxaloacetate, but is also able to reduce 
α-ketoglutarate  to  L2-hydroxyglutaric  acid  (L2-HGA). 
L2-HGA has no known metabolic function. It is converted 
back  to  α-ketoglutarate  by  L2-hydroxyglutaric  acid 
dehydrogenase (L2-HGDH). Thus, L2-HGDH ensures that 
the functionless L2-HGA does not accumulate in the cells of 
normal animals, in other words, it ensures metabolic repair 
(Rzem et al. 2004) (Figure 3). 
When  a  mutated  L2-HGDH  results  in  a  non-functional 
enzyme,  L2-HGA  accumulates.  Markedly  increased 
L2-HGA levels can be measured in CSF, plasma and urine in 
affected individuals (Rzem et al. 2004; Steenweg et al. 2010) 
but the authors are not aware of any publication proving 
accumulation  of  this  substance  in  astrocytes  or  any  other 
neurons.  L2-HGDH  is  most  active  in  the  brain  (Sanchez-
Masian et al. 2012); this may explain why neurological signs 
predominate in affected animals. L2-HGA has been shown to 
cause oxidative stress – it inhibits mitochondrial creatinine 
kinase  in  the  cerebellum  and  may  also  inhibit  glutamate-
dependent pathways, as it is a structural analogue of this 
common  neurotransmitter  substance  (Rzem  et  al.  2004).  It 
is this oxidative stress that was thought to be responsible 
for the astrocyte vacuolation observed on histopathological 
sections of an affected dog’s brain (Scurrell et al. 2008). 
Affected humans usually show clinical signs before they are 
seven years old (Kranendijk et al. 2012) but, as signs may 
be subtle and/or non-specific, diagnosis may be delayed as 
in this case (Abramson et al. 2003; Patay et al. 2012; Weimar 
et  al.  2012).  Clinical  signs  shown  by  both  species  include 
ataxia, dementia and seizures. In dogs, signs of dementia 
may  include  head  pressing,  getting  trapped  in  corners, 
hyperactivity,  aggression,  lethargy  or  attention  seeking 
(Farias et al. 2012). Dogs show behavioural changes and/or 
loss  of  learnt  behaviour,  whilst  behavioural  problems  are 
reported in 32% and psychomotor delay in 93% of humans. 
Disorientation,  hypermetria  and  tremors  are  reported  in 
dogs,  whilst  82%  of  humans  specifically  show  cerebellar 
ataxia with intention tremors (Steenweg et al. 2010). Thirty-
eight percent of people also show extrapyramidal signs, such 
as involuntary movements, inability to initiate movement, 
tremor and muscle spasm. Owners have observed muscle 
stiffness and fatigue with exercise in affected dogs, whilst 
40%  of  human  patients  show  hypotonia  progressing  to 
spasticity (Abramson et al. 2003). Some dogs show periodic 
exacerbation of clinical signs that may last for minutes to 
days.  In  contrast,  clinical  signs  are  slowly  progressive  in 
humans  and  periodic  exacerbations  are  not  commonly 
reported. Many dogs will show only one or two of the above 
signs and some may be so subtle that the owner considers 
the dog to be normal (Abramson et al. 2003). In both species 
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mutation that causes a malfunctioning L2-HGDH, L2-HGA accumulates in cells, which eventually disrupts metabolic pathways 
and causes clinical signs.  
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Acetyl-CoA  enters  the  mitochondrion  and  is  converted  to  water  and  carbon  dioxide, 
whilst NAD+ is reduced to NADH. NADH enters the oxidative phosphorylation pathway to 
produce ATP and thereby energy that can be used in other metabolic processes. L-malate 
dehydrogenase  converts  malate  to  oxaloacetate.  The  reaction  is  reversible.  In  fact,  in 
isolation, it favours malate production (malate can leave the mitochondrion, be converted 
back to oxaloacetate in the cytoplasm, which can then enter gluconeogenesis). L-malate 
dehydrogenase is not specific to malate and oxaloacetate: it can also convert α- ketoglutarate 
to  L-2  hydroxyglutaric  acid  (L2-HGA).  L2-hydroxyglutarate  dehydrogenase  (L2-HGDH)  is 
bound to mitochondrial membranes (Rzem et al. 2004) and converts this molecule that has 
no known biological function back to α - ketoglutarate. In patients with a genetic mutation 
that  causes  a  malfunctioning  L2-HGDH,  L2-HGA  accumulates  in  cells,  which  eventually 
disrupts metabolic pathways and causes clinical signs. 
FIGURE 3: Citric acid cycle and L2-hydroxyglutraic aciduria.
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the extent of the neurological compromise does not appear to 
be related directly to the severity of the aciduria (Abramson 
et al. 2003). In humans, it has not been possible to associate 
different  mutations  with  different  clinical  manifestations 
(Steenweg et al. 2010).
On MRI, both species show T2 hyperintensity in peripheral 
subcortical  white  matter  as  well  as  in  grey  matter  of  the 
thalamus, basal ganglia, globus pallidus, caudate and dentate 
nuclei  (Penderis  et  al.  2007;  Steenweg  et  al.  2010).  Diffuse 
oedema, manifesting as a subtle T1 hypointensity without 
contrast  enhancement,  is  sometimes  reported  (Abramson 
et  al.  2003).  In  addition,  humans  may  show  cerebellar 
atrophy, macrocephaly and may also have an increased risk 
of brain tumours (Aghili, Zahedi & Rafiee 2009; Kranendijk 
et al. 2012). To the authors’ knowledge, none of these have 
been  reported  in  dogs.  Because  the  extensive  grey  matter 
changes  in  dogs  are  usually  symmetrical,  inexperienced 
viewers  may  overlook  them.  In  addition,  other  breed-
associated  polioencephalopathies  may  have  similar  MRI 
lesions  (Abramson  et  al.  2003).  Referral  to  a  veterinary 
diagnostic imaging specialist is thus advised.
A  full  post  mortem  study  of  an  affected  SBT  found  no 
macroscopic  changes.  Histopathological  changes  were 
restricted  to  the  brain.  There  were  marked  spongiform 
changes in the astrocytes of the cerebral cortex, thalamus, 
cerebellum and brainstem. Grey matter was most severely 
affected (Scurrell et al. 2008). In humans, spongiform changes 
are most severe in the subcortical white matter (Penderis et al. 
2007). Thus, histopathological changes correspond to those 
found on MRI. It is not clear why the distribution of the most 
severe lesions differs between humans and dogs (Abramson 
et al. 2003).
Routine  haematology,  serum  biochemistry  and  in-house 
urine analysis are typically normal (Scurrell et al. 2008) and 
the hyposthenuria in this patient was probably a side effect 
of phenobarbitone treatment.
Routine  GC-MS  detects  the  presence  of  2-hydroxyglutaric 
acid in the urine, but does not determine chirality. L2-HGAU 
must  be  differentiated  from  D-2  hydroxyglutaric  aciduria 
(D2-HGAU),  isolated  cases  of  which  have  been  reported 
in  dogs  (Abramson  et  al.  2003).  In  humans,  two  types  of 
congenital  D2-HGAU,  as  well  as  D,L-2  hydroxyglutaric 
aciduria,  have  been  described  (Kranendijk  et  al.  2012). 
To  complicate  matters,  in  humans,  D2-HGAU  has  been 
associated with other errors of metabolism, for example, a 
skeletal dysplasia resulting in metaphyseal chondromatosis 
and multiple Acyl-CoA dehydrogenase deficiency. Lastly, it 
has been observed as an acquired mutation in patients with 
glioma and acute myeloid leukaemia (Kranendijk et al. 2012). 
There is no reason why these errors of metabolism would 
not occur in dogs, thus all of these should be considered as a 
differential diagnosis for a dog with high 2-hydroxyglutaric 
acid  levels  in  the  urine.  In  humans,  clinical  signs  and 
MRI  changes  may  often  distinguish  these  conditions,  but 
confirmation of chirality and genetic testing are necessary for 
a complete work-up (Kranendijk et al. 2012). Urine GC-MS 
would  be  an  appropriate  screening  tool  for  L2-HGAU  in 
encephalopathic dogs of breeds other than SBT. Dogs with 
a 2-hydroxyglutaric acid spike in their urine may not have 
L2-HGAU, but the disease can be excluded in dogs without 
one.
Elevated lysine in the CSF, plasma and urine has been noted 
in some humans and dogs with L2-HGAU, whilst some had 
elevated  urine  cysteine  and/or  arginine  (Abramson  et  al. 
2003). As high urine lysine decreases absorption of cysteine, 
ornithine and arginine in the proximal convoluted tubules, 
increased loss of these four amino acids may be interrelated 
(Abramson et al. 2003). Urine or plasma amino acid levels 
were not quantified in this case, but are of value in detecting 
other  metabolic  encephalopathies,  for  example,  multiple 
Acyl-CoA dehydrogenase deficiency and maple syrup urine 
disease (MSUD). Elevated urine lactate has been reported in 
one person with L2-HGAU (Barth et al. 1998).
More than 80 different mutations of L2-HGDH that can result 
in a non-functional enzyme and clinical signs of L2-HGAU 
have been documented in humans (Kranendijk et al. 2012). 
Such genetic heterogeneity should be anticipated amongst 
dogs.  Indeed,  a  different  L2-HGDH  mutation  has  already 
been described in YRT (Farias et al. 2012). Genetic screening 
is by its nature specific to a known mutation and cannot be 
used to exclude the disease. It is, however, the only way in 
which carriers can be detected. Genetic screening and GC-MS 
thus have complimentary roles in the diagnosis of L2-HGAU. 
L2-HGAU  is  incompletely  understood  and  there  is  no 
specific treatment for dogs or humans at present (Penderis 
et  al.  2007).  Humans  with  better-characterised  organic 
acidurias  are  treated  with  dietary  protein  restriction 
and  appropriate  amino  acid,  mineral  and  vitamin 
supplementation (Kolker et al. 2012; Penderis et al. 2007; Van 
der Watt et al. 2010). The efficacy of such supplementation of 
precursors is likely to vary depending on the nature of the 
underlying mutation as well as whether any normal enzyme 
is present in the particular patient. Supplementation with 100 
mg riboflavin once daily improved neurological function and 
markedly decreased L2-HGA secretion in the urine of two of 
three children with L2-HGAU in whom its use is reported 
(Kranendijk  et  al.  2012;  Yilmaz  2009).  Riboflavin  (Vitamin 
B2) is bound to an ADP molecule to form flavin adenine 
dinucleotide (FAD). Flavin adenine dinucleotide is a co-factor 
for L2-HGDH (Yilmaz 2009). A diet supplemented with FAD 
and levocarnitine chloride improved clinical signs in another 
human (Samuraki et al. 2008). A lysine-restricted diet was 
offered to one dog with concurrently elevated plasma lysine 
levels, but the patient refused to eat it (Farias et al. 2012). Such 
a diet was not tested in this SBT, as her lysine status was not 
known. In dogs with seizures, phenobarbitone at 3 mg/kg 
appears effective at controlling clinical signs (Abramson et al. 
2003; Sanchez-Masian et al. 2012). In the SBT described here, 
it  is  believed  that  the  phenobarbitone  acted  as  a  sedative 
during  the  period  of  acute  exacerbation  that  prompted Case Report
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investigation. The dose was reduced to 15 mg in the morning 
and 30 mg in the evening, but was not discontinued in the 
hope that it might suppress another period of dementia. 
The  therapeutic  effect  of  either  of  the  interventions  used 
in this case is difficult to assess in this dog, as her severe 
manifestations were episodic and uncommon, she only lived 
for 16 months post diagnosis and she was never off medication 
again.  This  case  does  confirm  previous  observations  that 
some mildly affected individuals may remain acceptable pets 
despite the limited scope of current treatment options.
Conclusion
To the authors’ knowledge, this is the first report of L2-HGAU 
in a South African SBT. The aim of this report is to raise 
awareness of this condition in the SBT breed in South Africa 
for two reasons. The first is so that colleagues can encourage 
breeders to screen breeding stock prior to mating. At least 46 
carrier dogs have already been identified in South Africa and 
11% of two overseas convenience samples of clinically normal 
SBT  were  carriers.  Heterozygotes  are  asymptomatic  but 
unwittingly mating two carriers is likely to result in clinically 
affected pups. Some affected dogs have clinical signs that 
are vague and may even be considered a cute quirk or ‘just 
a Staffie thing’ by some owners. Nevertheless, even mildly 
affected individuals should not be bred because all offspring 
will at least be carriers and subsequent homozygous offspring 
could be a great deal more compromised. The second reason 
is  so  that  colleagues  consider  genetic  screening  on  SBT 
showing  consistent  neurological  signs,  as  this  potentially 
avoids having to do more invasive or expensive diagnostic 
testing. There may be further mutations causing L2-HGAU 
in  dogs,  just  as  there  are  over  80  described  in  humans 
(Kranendijk et al. 2012). For this reason, urine organic acids 
should  be  determined  in  dogs  showing  consistent  clinical 
signs or MRI changes but whose genetic test suggests they 
are unaffected.
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